Belzutifan for Advanced Pheochromocytoma or Paraganglioma
Belzutifan showed antitumor activity with durable responses in participants with advanced pheochromocytoma or paraganglioma. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; LITESPARK-015 ClinicalTrials.gov number, NCT04924075.).
Authors
- Alfredo Berruti (ORCID: https://orcid.org/0000-0002-3956-0043)
- Tobias Else (ORCID: https://orcid.org/0000-0002-2262-0011)
- Girish S. Naik (ORCID: https://orcid.org/0000-0002-2832-0001)
- Rohini Sharma (ORCID: https://orcid.org/0000-0003-2441-549X)
- Sophie Moog (ORCID: https://orcid.org/0000-0001-9920-0480)
- Knut Mai (ORCID: https://orcid.org/0000-0003-0126-3155)
- Andreas Hallqvist (ORCID: https://orcid.org/0000-0002-3705-194X)
- Martin Faßnacht (ORCID: https://orcid.org/0000-0001-6170-6398)
- Edward M. Wolin (ORCID: https://orcid.org/0000-0003-3992-8722)
- Alexander Gozman
- Jaydira Del Rivero (ORCID: https://orcid.org/0000-0001-9710-4030)
- Elena Artamonova
- Camilo Jiménez (ORCID: https://orcid.org/0000-0002-5292-3355)
- Othon Iliopoulos (ORCID: https://orcid.org/0000-0002-4444-6157)
- Olivier Huillard (ORCID: https://orcid.org/0000-0001-9764-0845)
- Rocio García‐Carbonero (ORCID: https://orcid.org/0000-0002-3342-397X)
- Alice Durand (ORCID: https://orcid.org/0009-0008-4541-7500)
- Raymond Woo-Jun Jang
- Francesca Spada (ORCID: https://orcid.org/0000-0003-3642-0798)
- Amos Odeleye-Ajakaye
- Mikkel Andreassen (ORCID: https://orcid.org/0000-0002-1656-3516)
- Jaume Capdevila (ORCID: https://orcid.org/0000-0001-8017-9941)
- Staffan Welin
- Joseph D. Ruether
- Andrew Hendifar
Institutions
- Hebron University (PS)
- Cedars-Sinai Medical Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National Institutes of Health (US)
- Uppsala University Hospital (SE)
- The University of Texas MD Anderson Cancer Center (US)
- University of Calgary (CA)
- University of Michigan (US)
- Sahlgrenska University Hospital (SE)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Rigshospitalet (DK)
- Humboldt-Universität zu Berlin (DE)
- European Neuroendocrine Tumor Society (DE)
- Massachusetts General Hospital (US)
- Hôpital Cochin (FR)
- Ministry of Health (ES)
- Comprehensive Cancer Center Mainfranken (DE)
- Hospital Universitario 12 De Octubre (ES)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Hôpitaux Universitaires Paris-Ouest (FR)
- Hôpital Edouard Herriot (FR)
- Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale (FR)
- Vall d'Hebron Hospital Universitari (ES)
- National Cancer Institute (US)
- German Institute of Human Nutrition (DE)
- Imperial College London (GB)
- European Institute of Oncology (IT)
- University of Brescia (IT)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1056/nejmoa2504964
- Citations
- 12
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 24.08